FDA approves Spiriva (tiotropium) for kids age 6+ with asthma

The FDA has expanded the indication for tiotropium (Spiriva Respimat) to include children age 6 and older, based on efficacy data similar to that in adults. Tiotropium (Spiriva Respimat) was approved by FDA in 2015 for adults with asthma after clinical trials showed benefit of Spiriva as an add-on therapy to patients with persistent asthma [… read more]

The post FDA approves Spiriva (tiotropium) for kids age 6+ with asthma appeared first on PulmCCM.

Source: PulmCCM

Leave a Reply